STOCK TITAN

MedTech Acquisition Corporation - MTAC STOCK NEWS

Welcome to our dedicated page for MedTech Acquisition Corporation news (Ticker: MTAC), a resource for investors and traders seeking the latest updates and insights on MedTech Acquisition Corporation stock.

MedTech Acquisition Corporation (MTAC) is a special purpose acquisition company (SPAC) that focuses on merging with or acquiring businesses in the medical technology sector. Established to leverage its team's extensive experience in healthcare and finance, MedTech Acquisition Corporation aims to bring innovative medical technologies to the public market.

MedTech Acquisition Corporation’s core mission is to identify and partner with promising medical technology companies that have the potential to transform healthcare. This includes companies involved in medical devices, diagnostics, digital health, and other health-related sectors. Recently, MedTech Acquisition Corporation has been actively involved in discussions with several high-potential companies, positioning itself at the cutting edge of medical innovation.

The company's financial condition remains sound, with a strong capital base to support its acquisition goals. MedTech Acquisition Corporation continuously seeks partnerships that can offer strategic value and drive growth. For instance, their recent engagement with TriSalus Life Sciences showcases their commitment to advancing therapeutic developments.

Stay tuned for the latest updates and developments as MedTech Acquisition Corporation continues to play a significant role in the medical technology landscape.

Rhea-AI Summary
TriSalus completes merger with MedTech, stock to begin trading on Nasdaq. Cash runway through mid-2024. Advances in technology and clinical trials. Positive clinical data. TriNav net sales: $8.4M (2021), $12.4M (2022), projected $19.2M (2023). TriNav LV device receives FDA clearance. SD-101 shows immune effects in liver and blood. Phase 1 data readouts planned Q4 2023, Phase 2 trial in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
MedTech Acquisition Corporation (Nasdaq: MTAC) has adjourned its special meeting of stockholders without conducting any business. The meeting is being held to vote on proposals related to the proposed business combination with TriSalus Life Sciences. The meeting has been rescheduled for August 8, 2023, and will be held virtually. Stockholders can attend and participate online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
-
Rhea-AI Summary
TriSalus Life Sciences announces additional Phase 1 clinical data from PERIO-01 trial at ASCO 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

TriSalus Life Sciences has announced new Phase 1 clinical data at the AACR 2023 Annual Meeting regarding its Pressure-Enabled Regional Immuno-Oncology (PERIO-01) trial for uveal melanoma with liver metastases. The trial, utilizing the investigational drug SD-101 delivered via the TriNav Infusion System, aims to enhance systemic checkpoint inhibitors' effectiveness. Of 27 enrolled patients, treatment-related adverse events were mostly non-serious, with one significant event reported. Encouragingly, ctDNA and circulating tumor cell levels decreased in several patients, indicating potential improved survival outcomes. TriSalus is preparing for a business combination with MedTech Acquisition Corporation (MTAC), projected to list under the ticker TLSI, pending necessary approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

TriSalus Life Sciences announced the appointment of Jim Alecxih as President of Device Technology Business. With over 30 years of experience in product development and commercialization, Alecxih will oversee the growth of the TriNav Infusion System, which has been used in over 17,000 procedures. The Company is in the process of going public through a merger with MedTech Acquisition Corporation (ticker: MTAC) expected to close in Q2 2023, pending shareholder approval. TriSalus aims to disrupt cancer treatment for liver and pancreatic tumors through innovative drug delivery technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

TriSalus Life Sciences, an oncology firm, has released new data on its Pressure-Enabled Regional Immuno-Oncology (PERIO) studies for treating liver tumors. The ongoing PERIO-01 and PERIO-02 trials assess SD-101's intravascular delivery using the TriNav Infusion System. Results show a decrease in circulating tumor DNA for uveal melanoma patients treated with SD-101 and nivolumab, indicating potential survival benefits. With 42 patients enrolled as of February 2023, TriSalus anticipates additional data by Q2 2023 and is expanding its clinical sites ahead of Phase 2 programs set for later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

TriSalus Life Sciences is advancing its Pressure-Enabled Regional Immuno-Oncology clinical program through a business combination with MedTech Acquisition Corporation (MTAC). The company has opened five additional PERIO-01 clinical trial sites across major U.S. institutions, including Stanford and UCLA, for its investigational drug SD-101. The trials aim to improve immunotherapy efficacy in patients with liver metastases from uveal melanoma and those with hepatocellular carcinoma. Promising pre-clinical data supports the potential of SD-101 to enhance therapy outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary

MedTech Acquisition Corporation (NASDAQ: MTAC) has postponed its special meeting of stockholders to December 12, 2022, to secure more votes for the Extension Amendment. This amendment seeks to extend the deadline for completing a business combination from December 22, 2022, to June 22, 2023. The company is currently working to finalize a merger with TriSalus Life Sciences, Inc.. Stockholders as of the record date, October 24, 2022, can still vote regardless of share sales.

Approval of the merger is critical for the company’s future as it plans to rebrand as TriSalus Life Sciences upon completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
-
Rhea-AI Summary

TriSalus Life Sciences has announced a definitive merger agreement with MedTech Acquisition Corporation (NASDAQ: MTAC). This merger aims to transform cancer treatment through innovative drug delivery technologies, specifically targeting liver and pancreatic tumors. Post-transaction, TriSalus expects a market capitalization of approximately $244.4 million. The merger will facilitate the commercialization of its FDA-cleared TriNav® Infusion System and advance its investigational therapy, SD-101. The deal is projected to close in Q1 2023, bringing TriSalus more than $60 million in cash, including $50 million from a convertible note.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
Rhea-AI Summary

MedTech Acquisition Corporation (Nasdaq: MTAC) and Memic Innovative Surgery Ltd. have mutually agreed to terminate their business combination agreement due to market volatility. This decision, effective immediately, reflects the challenges posed by recent global events. Despite the termination, both companies express optimism, with Memic highlighting the successful adoption of its Hominis system by leading U.S. hospitals, aimed at advancing surgical practices in women's health and general surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags

FAQ

What is the market cap of MedTech Acquisition Corporation (MTAC)?

The market cap of MedTech Acquisition Corporation (MTAC) is approximately 83.9M.

What is MedTech Acquisition Corporation's primary business focus?

MedTech Acquisition Corporation focuses on merging with or acquiring businesses in the medical technology sector.

What sectors does MedTech Acquisition Corporation target?

MTAC targets companies in medical devices, diagnostics, digital health, and other healthcare-related sectors.

How does MedTech Acquisition Corporation create value?

MTAC leverages its healthcare and finance expertise to identify and partner with promising medical technology companies.

What is a recent partnership involving MedTech Acquisition Corporation?

MTAC recently engaged with TriSalus Life Sciences, highlighting its interest in therapeutic developments.

What is the financial condition of MedTech Acquisition Corporation?

MTAC maintains a strong capital base to support its acquisition goals and strategic partnerships.

How does MedTech Acquisition Corporation stay innovative?

MTAC stays at the cutting edge of medical innovation by actively seeking high-potential companies in the healthcare sector.

What is a SPAC?

A SPAC, or Special Purpose Acquisition Company, is a company formed to raise capital through an IPO to acquire existing companies.

How can I stay updated on MedTech Acquisition Corporation's news?

You can stay informed by following MTAC's official announcements and news sources like StockTitan.

Who are the key players behind MedTech Acquisition Corporation?

MTAC is led by a team with extensive experience in healthcare and finance, dedicated to advancing medical technology.

Why is MedTech Acquisition Corporation significant in the market?

MTAC is significant because it helps bring groundbreaking medical technologies to the public market, transforming healthcare.

MedTech Acquisition Corporation

Nasdaq:MTAC

MTAC Rankings

MTAC Stock Data

83.86M
549.65k
84.52%
17.17%
0.05%
Shell Companies
Financial Services
Link
United States
Greenwich